Increased Release of Cytokines from Human Peripheral Blood Mononuclear Cells by the β-Galactoside-Specific Lectin from Clinically Applied Mistletoe Extract

  • T. Hajto
  • K. Hostanska
  • K. Frei
  • H. J. Gabius
Conference paper


Therapeutic modulation of immune functions offers an attractive concept in tumor therapy. The principal obstacle to the formulation of a rational approach to immunomodulation therapy is the only partially unravelled complexity of the relations between effector cell and a network of cytokines. Any contribution to the basic understanding of this aspect can be favorably translated into clinical benefit in hospital practice. Here we test the assumption that lectins have immunomodulatory potency by augmenting cytokine secretion, using the concept of the supposed physiological relevance of protein-carbohydrate interactions [1, 2]. The selection of the lectin was empirically based on the knowledge that a proprietary extract from mistletoe (Iscador), containing a ß-galactoside-specific lectin-I (ML-I), exhibits immunomodulatory potency [3, 4].


Cytolytic Activity Human Peripheral Blood Mononuclear Cell Viscum Album Peripheral Blood Mononuclear Cell Culture Specific Polyclonal Antibody 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Gabius HJ (1987) Endogenous lectin in humans and the immune system. Cancer Invest 5:39–46PubMedCrossRefGoogle Scholar
  2. 2.
    Gabius HJ (1988) Mammalian lectin:their structure and their glycobiological and glycoclinical roles. ISI Atlas Sci Biochem 1:210–214Google Scholar
  3. 3.
    Hajto T (1986) Immunomodulatory effects of Iscador:a Viscum album preparation. Oncology 43 [Supl l]:51–65PubMedCrossRefGoogle Scholar
  4. 4.
    Hajto T, Hostanska K, Gabius HJ (1989) Modulatory potency of the ß-galactoside-specific lectin from mistletoe extract ( Iscador) on the host defense system in vivo in rabbits and patients. Cancer Res 49:4803–4808PubMedGoogle Scholar
  5. 5.
    Gabius HJ, Engelhardt R, Cramer F, Bätge R, Nagel GA (1985) Pattern of endogenous lectins in a human epithelial tumor. Cancer Res 45:253–257PubMedGoogle Scholar
  6. 6.
    Gabius JH, Bandlow G, Schirrmacher V, Nagel GA, Vehmeyer K (1987) Differential expression of endogenous sugar-binding proteins (lectins) in murine tumor model system with metastatic capacity. Int J Cancer 39:643–648PubMedCrossRefGoogle Scholar
  7. 7.
    Gabius HJ, Engelhardt R (1988) sugar receptors of different types in human metastases to lung and liver. Tumour Biol 9:21–36PubMedCrossRefGoogle Scholar
  8. 8.
    Frei K, Siepl C, Groscurth P, Bodmer S, Schwerdel C, Fontana A (1987) Antigen presentation and tumor cytotoxicity by interferon-treated microglial cells. Eur J Immunol 17:1271–1278PubMedCrossRefGoogle Scholar
  9. 9.
    Ditter B, Becker KB, Urbaschek R, Urbaschek B (1983) Quantitativer Endotoxin-Nachweis. Automatisierter, kinetischer Limulus-Amöbozyten-Lysat-Mikrotiter-Test mit Messung probenabhängiger Interferenzen. Arzneimittelforschung 5:681–687Google Scholar
  10. 10.
    Oldham R (1986) Biotherapy:the fourth modality of cancer treatment. J Cell Physiol 4 [Suppl]:91–99CrossRefGoogle Scholar

Copyright information

© Springer-Verlag, Berlin Heidelberg 1990

Authors and Affiliations

  • T. Hajto
  • K. Hostanska
  • K. Frei
  • H. J. Gabius

There are no affiliations available

Personalised recommendations